V8 Peptides — Engineered Performance
Research Library
Tesamorelin Clinical Literature: A Bench-Scientist Guide
TesamorelinPreclinical

Tesamorelin Clinical Literature: A Bench-Scientist Guide

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

Tesamorelin has a human trial literature, and a lab reader should read it as design, not as advice. A 2007 randomized trial reported visceral fat down 15.2% versus up 5.0% on placebo and IGF-I up 81.0% in 412 people with HIV and abdominal fat; later analyses were responder-based and post hoc. Results apply to that population only. This guide gives no doses. The research peptide is supplied for laboratory research use only.

Tesamorelin is unusual among research peptides in having a large published human clinical literature, which is both useful and a hazard for a bench scientist. It is useful because the trials report endpoints, such as visceral fat, triglycerides and IGF-I, that suggest what to measure in a preclinical model. It is a hazard because a reader can easily slide from "a trial reported X in a defined population" to "the molecule does X", and neither the trials nor this site support that step for any use outside a laboratory. This article summarises what the main published trials reported, with their design features, so that a laboratory reader can see what the literature is and is not. It gives no doses and no advice. The tesamorelin research peptide from V8 Peptides is supplied for laboratory research use only.

For the compound's chemistry and handling, see the tesamorelin research overview and what is tesa. This guide is about the clinical papers as documents. If you are planning a blend design, the tesamorelin and ipamorelin blend explanation and the sermorelin research overview cover neighbouring GHRH-axis compounds.

What the molecule is

The product page describes tesamorelin as a synthetic analog of human growth-hormone-releasing hormone (GHRH) that contains the complete 44-amino-acid GHRH sequence with one addition, a trans-3-hexenoic acid group on the N-terminal tyrosine. The page states that this small acyl cap makes the peptide more resistant to cleavage by dipeptidyl peptidase-4, and gives a molecular weight of roughly 5.1 kDa and the formula C221H366N72O67S, with ≥98% HPLC purity. A non-clinical paper from the program that developed it uses the code name TH9507 and describes the same modification, a trans-3-hexenoyl moiety on Tyr1 of hGRF(1-44)NH2, which was found to be resistant to dipeptidyl aminopeptidase-IV deactivation (Ferdinandi and colleagues, 2007). The details of the modification are covered in the hexenoyl modification explained.

The anchor trial and what it measured

The trial most often cited randomly assigned 412 people with HIV, 86% of them men, who had accumulation of abdominal fat, to receive a daily subcutaneous administration of tesamorelin or placebo for 26 weeks. The primary endpoint was the percent change in visceral adipose tissue (VAT) measured by computed tomography. Secondary endpoints included triglycerides, the ratio of total cholesterol to HDL cholesterol, IGF-I and self-assessed body image, with glycemic measures tracked as well (Falutz and colleagues, 2007). Reported results, as stated in the abstract:

EndpointTesamorelin groupPlacebo group
Visceral adipose tissueDecreased by 15.2%Increased by 5.0%
TriglyceridesDecreased by 50 mg/dLIncreased by 9 mg/dL
Total cholesterol to HDL ratioDecreased by 0.31Increased by 0.21
IGF-IIncreased by 81.0%Decreased by 5.0%
Glycemic measuresNo significant differences
Adverse eventsDid not differ significantly between groups, but more participants in the tesamorelin group withdrew because of an adverse event

Three things stand out for a laboratory reader. The primary endpoint is imaging-based, so any preclinical analogue would also need an imaging or direct tissue measure. The pharmacodynamic marker, IGF-I, moved far more than the fat endpoint, which is the expected signature of GHRH-receptor activation upstream of growth hormone; the biology of that step is in the research overview. And the safety statement is two-sided: no significant difference in adverse events overall, but more withdrawals because of one in the active group. Both halves of that sentence are in the abstract and both belong in any summary.

Responder analyses and why they need care

A follow-up analysis pooled two phase III randomized, double-blind studies in which participants were assigned 2:1 to tesamorelin or placebo for 26 weeks; at week 26, those initially on tesamorelin were re-randomized to continue or switch to placebo for another 26 weeks. In 402 participants analysed per protocol, a "responder" was defined a priori as a person with at least 8% reduction in VAT. Compared with non-responders, responders had greater reductions in triglycerides and attenuated changes in fasting glucose, HbA1c and other glucose-homeostasis measures, with similar patterns for adiponectin (Stanley and colleagues, 2012).

The design matters. A responder analysis divides people according to an outcome and then compares other outcomes between the groups. That is a legitimate exploratory approach, and the paper calls its analyses post hoc, but it cannot show that the drug caused the metabolic differences between responders and non-responders, only that they were associated with the amount of VAT change. A bench scientist can take from this the hypothesis that metabolic readouts track the size of an adiposity change, which is a testable idea in a preclinical model, not an established mechanism.

Liver enzymes and what happened after the study drug stopped

Another analysis of the same two phase III trials, covering 806 HIV-infected participants with abdominal obesity, asked whether VAT reductions with tesamorelin were associated with changes in the liver enzymes ALT and AST. Among participants with baseline ALT or AST above 30 U/L who were assigned to tesamorelin, VAT responders had greater reductions in ALT and AST than non-responders at 26 weeks, and the improvement among responders persisted at 52 weeks even in those switched to placebo, despite partial reaccumulation of VAT (Fourman and colleagues, 2017). The wording of the abstract is associational, and that is how it should be repeated. The reaccumulation of VAT after discontinuation is also worth noting: the measured effect on fat was not described as permanent.

Newer data and why population matters

The older phase III trials were conducted before integrase inhibitors became a mainstay of HIV antiretroviral regimens. A 2024 analysis used a randomized, double-blind trial of 61 people with HIV and metabolic dysfunction-associated steatotic liver disease to look at the subgroup of 38 on integrase-inhibitor-based regimens at baseline, of whom 15 on tesamorelin and 16 on placebo completed 12 months. Visceral fat, hepatic fat and trunk-to-appendicular fat ratio, measured by MRI, proton MR spectroscopy and DEXA, declined more in the tesamorelin arm, and adverse events, including hyperglycemia, occurred at similar frequency between groups (Russo and colleagues, 2024). The same paper describes tesamorelin as the only FDA-approved product for abdominal fat accumulation in people with HIV; that is the authors' statement in the abstract and this site draws no regulatory conclusion from it. The point for a reader is the sample size: the integrase-inhibitor result comes from 31 completers in a subgroup of a parent trial, which is a small number.

A meta-analysis of five randomized controlled trials against placebo in adults with HIV, searched through July 2025, reported pooled reductions in visceral adipose tissue, trunk fat, limb fat, hepatic fat percentage and waist circumference, with an increase in lean body mass and no significant change in subcutaneous adipose tissue or BMI. It also lists arthralgia, myalgia, paresthesia and site reactions such as erythema among adverse events (Badran and colleagues, 2026).

A reading guide for the trial literature

QuestionWhere to look in the paperWhy it matters
Who was studied?Population and inclusion criteriaA result in people with HIV and abdominal fat accumulation does not transfer to other populations
What was the primary endpoint?MethodsSecondary and post hoc results are weaker evidence
How long?Study duration and follow-up26- and 52-week results are not lifelong results
What happened after stopping?Discontinuation or re-randomization armsShows whether effects persisted
Was the analysis pre-specified?Statistical analysis plan, "post hoc"Separates confirmatory from exploratory
What were the harms?Adverse events and withdrawalsA neutral overall rate can hide imbalances in specific events or withdrawals

What bench researchers can take from it

  • Choose biomarkers on purpose. IGF-I is the pharmacodynamic readout reported in the trial and in non-clinical work (Ferdinandi and colleagues, 2007), so it is the natural receptor-activation marker in a preclinical design.
  • Separate target engagement from downstream effects. A GHRH-receptor assay in cells tests engagement; adiposity and liver endpoints belong to animal models.
  • Do not import human parameters. The human regimens are not a basis for animal or cell concentrations; non-clinical studies reported their own parameters in their own species.
  • Verify the material. A trial used a defined, regulated product; a research vial needs its own certificate. Match the lot string to the COA page, and see tesamorelin purity testing.

Handling facts from the product page

The page gives the concentration arithmetic for the 10 mg vial: 2 mL of diluent gives 5 mg/mL and 1 mL gives 10 mg/mL, and larger peptides can take longer to dissolve, so allow a few minutes before judging clarity. The powder is stored at 2–8 °C routinely and −20 °C long term, protected from light, humidity and temperature swings; solutions are kept refrigerated, labelled with lot and concentration, and aliquoted once to avoid repeated freeze–thaw cycles. See tesamorelin reconstitution and storage for the procedure.

Limits of this summary

This article reports the abstracts of five papers. It does not evaluate their methods beyond what the abstracts state, it does not cover every trial, and it does not translate any trial result into advice. Nothing here describes the safety or effect of the research material sold on this site.

Related reading

Frequently asked questions

What is tesamorelin?

The product page describes it as a synthetic analog of human GHRH with the full 44-amino-acid sequence and a trans-3-hexenoic acid group on the N-terminal tyrosine, which increases resistance to dipeptidyl peptidase-4.

What was the main outcome of the 2007 trial?

The abstract reports that visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group over 26 weeks in 412 people with HIV and abdominal fat accumulation.

What other endpoints were reported in that trial?

Triglycerides fell by 50 mg/dL versus a rise of 9 mg/dL, the cholesterol to HDL ratio fell by 0.31 versus a rise of 0.21, and IGF-I rose by 81.0% versus a fall of 5.0%.

Were there differences in adverse events?

Adverse events did not differ significantly between groups, but more participants in the tesamorelin group withdrew because of an adverse event.

What is a responder analysis?

A grouping of participants by an outcome, here at least 8% VAT reduction, followed by comparison of other outcomes. It can show association but not cause.

Did effects persist after stopping?

A 2017 analysis reported that liver-enzyme improvements among VAT responders persisted at 52 weeks in those switched to placebo, despite partial reaccumulation of VAT.

Why does study population matter?

The trials enrolled people with HIV and abdominal fat accumulation. Results in that group do not transfer to other populations or to laboratory models.

Does this article give doses?

No. It reports trial designs and outcomes from abstracts and gives no doses or advice. Nothing here applies to the research material sold on this site.

How is the tesamorelin vial stored?

The product page states 2–8 °C routinely and −20 °C for long-term holding, protected from light, humidity and temperature swings.

Is tesamorelin from V8 for use in people or animals?

No. It is sold strictly for laboratory research use only.

Related reading: Tesamorelin GHRH Receptor Mechanism: Assay Design, Tesamorelin Lab Applications: Readouts and Checks, Tesamorelin Research Peptide in 2026: A Primer.

References

  1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375
  2. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. doi:10.1093/cid/cis251
  3. Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253-2259. doi:10.1097/QAD.0000000000001614
  4. Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. doi:10.1097/QAD.0000000000003965
  5. Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. doi:10.1016/j.orcp.2026.01.002
  6. Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. doi:10.1111/j.1742-7843.2007.00008.x

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.